FindTrial
Sign In

Effect of SLCO1B1 521T>C and 388 A>G polymorphism on efficacy and safety of atorvastatin

Effect of SLCO1B1 521T>C and 388 A>G polymorphism on efficacy and safety of atorvastatin

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019243
Enrollment
Unknown
Registered
2018-11-01
Start date
2017-11-01
Completion date
Unknown
Last updated
2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

case series:atorvastatin 20mg qn

Sponsors

Beijing Tongren Hospital,Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with clinical diagnosis of coronary heart disease or coronary atherosclerosis; 2. Aged 18 years old; 3. Have not taken lipid-lowering drugs, or have taken them but have stopped taking them for more than 4 weeks; 4. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Abnormal liver function; 2. Moderate to severe renal dysfunction; 3. Pregnancy and lactation women; Acute cerebrovascular accident, severe trauma, malignant tumor, and surgery patients within 6 months; 5. Hypothyroidism.

Design outcomes

Primary

MeasureTime frame
LDL-C;—

Countries

China

Contacts

Public ContactBAI YING

Beijing Tongren Hospital,Capital Medical University

felisha_bai@hotmail.com+86 15001033026

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026